Neurizon Appoints Chief Executive Officer
Filed with ASX · · 4 pages · English
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- Appendix 4E and 2026 Annual Report
- Neurizon Enters Strategic R&D Financing Facility
- HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027
- HEALEY Enrolment Complete - Topline Accelerated to Q2 CY27
- Neurizon executes long-term supply agreement with Elanco
Later from Neurizon Therapeutics
- NIH funds Expanded Access Program for NUZ-001 in ALS
- Neurizon Announces Partial Redemption of Convertible Notes
- FDA Type C Feedback, HEALEY trial potentially registrational
- Appendix 4C & Quarterly Update
- Trading Halt
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics